Jordan - Injectable medications for obesity and metabolic disorders
This is a business opportunity from an overseas buyer. Pitch for the business and explain how your company meets their requirements.
Details
- Opportunity closing date
- 11 April 2025
- Opportunity publication date
- 18 March 2025
- Opportunity type
-
Private Sector
- Industry
- Pharmaceuticals and biotechnology
- Enquiries received
- 1
- Value of contract
- to be confirmed
- Your guide to exporting
Description
Obesity metabolic disorder medications are designed to:
- support weight reduction
- improve insulin sensitivity
- decrease appetite
- enhance metabolism
The injections are widely used for treating obesity, type 2 diabetes, and metabolic syndrome.
Drug forms and administration
Most of these medications are available in injectable form, commonly administered via:
- subcutaneous (SC) injection – the most common route
- prefilled pens – designed for easy self-administration
Note: originators or biosimilars to known brands are acceptable.
To be considered for this opportunity, successful applicants must have:
- an active Companies House record
- an annual turnover of at least £500,000
- export experience to overseas markets, preferably to the Middle East
In the application, applicants should provide a description of how their products match the requirements in the export opportunity.
- Opportunity closing date
- 11 April 2025
- Value of contract
- to be confirmed
- The buyer is happy to talk to
- manufacturers
The deadline to apply for this opportunity has passed.
Visit the
opportunities page
to find another.